Brazilian Notebook: Key Themes From BIO Latin America
Executive Summary
Population size and favorable biosimilar policies highlight the opportunities for biotech in Brazil, but economic turmoil and other factors pose challenges.
You may also be interested in...
Brazil, Mexico Taking Divergent Paths On Regulatory Reform
Anvisa is in the process of trying to reduce some of its red tape, but the excessive bureaucracy at COFEPRIS is likely to remain in place for the foreseeable future.
Brazil's Limited Legal Framework On Biosimilar Interchangeability Could Actually Help Sponsors
Anvisa currently has no legislative authority to tell the Ministry of Health to refrain from providing biosimilar medications interchangeably, giving drugmakers an expanded opportunity to access Brazil's large patient population.
Biodiversity Law Reform Spurs Innovation, But Patent Backlog Remains
Brazil's new biodiversity research law is viewed as a step toward fostering biological innovation, but patent backlogs of 14 years still prove to be a major deterrent to conducting R&D in the country.